Katsuyama, H.; Hakoshima, M.; Umeyama, S.; Iida, S.; Adachi, H.; Yanai, H.
Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study. Biomedicines 2023, 11, 869.
https://doi.org/10.3390/biomedicines11030869
AMA Style
Katsuyama H, Hakoshima M, Umeyama S, Iida S, Adachi H, Yanai H.
Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study. Biomedicines. 2023; 11(3):869.
https://doi.org/10.3390/biomedicines11030869
Chicago/Turabian Style
Katsuyama, Hisayuki, Mariko Hakoshima, Shohei Umeyama, Sakura Iida, Hiroki Adachi, and Hidekatsu Yanai.
2023. "Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study" Biomedicines 11, no. 3: 869.
https://doi.org/10.3390/biomedicines11030869
APA Style
Katsuyama, H., Hakoshima, M., Umeyama, S., Iida, S., Adachi, H., & Yanai, H.
(2023). Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study. Biomedicines, 11(3), 869.
https://doi.org/10.3390/biomedicines11030869
